| Wang, Jin |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
RATIONALE 305, NCT03777657 / 2018-000312-24: Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma |
|
|
| Completed | 3 | 997 | Europe, Japan, US, RoW | Tislelizumab, BGB-A317, Placebo, Cisplatin, Oxaliplatin, Capecitabine, 5-FU | BeiGene | Gastric, or Gastroesophageal Junction Adenocarcinoma | 02/23 | 08/24 | | |
|
|
|
|
NCT04294511: Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of Osteosarcoma |
|
|
| Recruiting | 2 | 75 | RoW | Camrelizumab in Combination With Neoadjuvant Chemotherapy, PD-1 inhibitor | Sun Yat-sen University, Jiangsu HengRui Medicine Co., Ltd. | Osteosarcoma | 03/21 | 09/23 | | |
NCT04606108: Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of High-risk Soft Tissue Sarcoma |
|
|
| Recruiting | 2 | 62 | RoW | Camrelizumab in Combination With Neoadjuvant Chemotherapy, PD-1 inhibitor | Sun Yat-sen University, Jiangsu HengRui Medicine Co., Ltd. | Soft Tissue Sarcoma | 10/21 | 03/24 | | |
NCT05952128: Phase Ib/II Study of Fluzoparib in Combination With Dalpiciclib in Patients With Locally Advanced or Metastatic Sarcoma |
|
|
| Recruiting | 2 | 50 | RoW | Fluzoparib+ Dalpiciclib | Sun Yat-sen University, Jiangsu Hengrui Pharmaceutical Co., Ltd. | Sarcoma | 12/24 | 12/25 | | |
| Recruiting | 2 | 170 | RoW | HS-20093 | Hansoh BioMedical R&D Company | Osteosarcoma, Sarcoma | 12/25 | 12/27 | | |
NCT04390737: Evaluate the Safety and Clinical Activity of HH2853 |
|
|
| Recruiting | 1/2 | 254 | US, RoW | HH2853 Tablets | Haihe Biopharma Co., Ltd. | FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor | 12/25 | 12/25 | | |
NCT05815680: A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects |
|
|
| Completed | 1 | 48 | RoW | metformin, digoxin, IBI362, warfarin, atorvastatin | Innovent Biologics (Suzhou) Co. Ltd. | Overweight Subjects, Obese Subjects | 08/23 | 10/23 | | |
NCT05793450: Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment |
|
|
| Completed | 1 | 20 | RoW | IBI362 | Innovent Biologics (Suzhou) Co. Ltd. | Renal Impairment | 09/23 | 11/23 | | |
NCT06416787: Safety and Tolerability of IBI355 in Healthy Volunteers |
|
|
| Active, not recruiting | 1 | 32 | RoW | placebo, IBI355 | Innovent Biologics (Suzhou) Co. Ltd. | Healthy | 02/25 | 12/25 | | |
NCT06110338: Safety and Tolerance Study of IBI355 in Health Volunteers |
|
|
| Completed | 1 | 53 | RoW | placebo, IBI355 | Innovent Biologics (Suzhou) Co. Ltd. | Healthy Subjects | 09/24 | 09/24 | | |
NCT06711991: A Clinical Trial of TQC3927 Powder for Inhalation in Chronic Obstructive Pulmonary Disease |
|
|
| Not yet recruiting | 1 | 48 | RoW | TQC3927 powder for inhalation, TQC3927 powder for inhalation placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Obstructive Pulmonary Disease | 12/25 | 01/26 | | |
